vida: extract claims from 2024-xx-stanford-ibogaine-veterans-ptsd-n30

- Source: inbox/queue/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md
- Domain: health
- Claims: 2, Entities: 1
- Enrichments: 1
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s.md

@@ -73,4 +73,10 @@ Topics:
 
 **Source:** Papanicolas et al., JAMA Internal Medicine 2025
 
-Drug-related deaths contributed 71.1% of the increase in preventable avoidable deaths from external causes during 2009-2019, providing precise quantification of the deaths-of-despair mechanism's contribution to US mortality divergence. The study shows this operated across all 50 states with West Virginia experiencing the worst increase (+99.6 per 100,000) while even the best-performing state (New York, -4.9) could not escape the broader deterioration pattern.
+Drug-related deaths contributed 71.1% of the increase in preventable avoidable deaths from external causes during 2009-2019, providing precise quantification of the deaths-of-despair mechanism's contribution to US mortality divergence. The study shows this operated across all 50 states with West Virginia experiencing the worst increase (+99.6 per 100,000) while even the best-performing state (New York, -4.9) could not escape the broader deterioration pattern.
+
+## Extending Evidence
+
+**Source:** IHME GBD 2050 Forecast, December 2024
+
+IHME's 2050 forecast projects drug use disorder death rates will increase 34% from 19.9/100K (2022) to 26.7/100K (2050), suggesting the structural socioeconomic drivers persist even as acute fentanyl supply disruptions temporarily reduce mortality in 2024. The model treats 2024's fentanyl decline as cyclical rather than structural resolution.

domains/health/Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated.md

@@ -1,23 +1,14 @@
 ---
-description: Market incentives drive food companies to maximize addictiveness through armies of food scientists and psychologists while government subsidizes the resulting health crisis -- chronic disease now kills more than famine infectious disease and war combined
 type: claim
 domain: health
-source: "Architectural Investing, Ch. Dark Side of Specialization; Moss (Salt Sugar Fat); Perlmutter (Brainwash)"
+description: Market incentives drive food companies to maximize addictiveness through armies of food scientists and psychologists while government subsidizes the resulting health crisis -- chronic disease now kills more than famine infectious disease and war combined
 confidence: proven
+source: Architectural Investing, Ch. Dark Side of Specialization; Moss (Salt Sugar Fat); Perlmutter (Brainwash)
 created: 2026-02-28
-related_claims:
-  - ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway
-  - upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure
-  - food-insecurity-creates-bidirectional-reinforcing-loop-with-cvd-through-medical-costs-and-dietary-quality
-  - hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause
-  - hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022
-related:
-- famine disease and war are products of the agricultural revolution not immutable features of human existence and specialization has converted all three from unforeseeable catastrophes into preventable problems
-reweave_edges:
-- famine disease and war are products of the agricultural revolution not immutable features of human existence and specialization has converted all three from unforeseeable catastrophes into preventable problems|related|2026-03-31
-- The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24
-supports:
-- The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment
+related_claims: ["ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway", "upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure", "food-insecurity-creates-bidirectional-reinforcing-loop-with-cvd-through-medical-costs-and-dietary-quality", "hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause", "hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022"]
+related: ["famine disease and war are products of the agricultural revolution not immutable features of human existence and specialization has converted all three from unforeseeable catastrophes into preventable problems", "Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated"]
+reweave_edges: ["famine disease and war are products of the agricultural revolution not immutable features of human existence and specialization has converted all three from unforeseeable catastrophes into preventable problems|related|2026-03-31", "The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24"]
+supports: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment"]
 ---
 
 # Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated
@@ -58,4 +49,10 @@ Relevant Notes:
 
 Topics:
 - health and wellness
-- livingip overview
+- livingip overview
+
+## Supporting Evidence
+
+**Source:** IHME GBD 2050 Forecast, December 2024
+
+IHME forecasts 260 million Americans will be affected by obesity by 2050, with obesity accelerating biological aging by more than 2 years in nonsmoking adults and slowing life expectancy gains while widening racial health disparities. This represents the long-run structural trajectory of the obesity epidemic.

domains/health/ibogaine-federal-policy-priority-rests-on-single-n30-pilot-illustrating-veteran-constituency-acceleration-ahead-of-evidence-hierarchy.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: Trump's $50M ARPA-H ibogaine EO was driven by Stanford's 30-person uncontrolled pilot despite lacking Phase 3 evidence, demonstrating constituency-driven policy acceleration
+confidence: experimental
+source: Stanford University School of Medicine pilot study (n=30), Trump EO April 2026
+created: 2026-05-10
+title: Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies
+agent: vida
+sourced_from: health/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md
+scope: structural
+sourcer: Stanford University School of Medicine / CNN / NPR
+related: ["healthcare-ai-regulation-needs-blank-sheet-redesign", "the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access"]
+---
+
+# Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies
+
+The Stanford ibogaine study enrolled 30 veterans with PTSD, TBI, and/or substance use disorder in an overseas clinical setting (ibogaine is Schedule I in the US). At 1-month follow-up, participants self-reported 88% PTSD reduction, 87% depression reduction, and 81% anxiety reduction. The study had no control group, no blinding, single timepoint, and a non-representative veteran population. Despite these severe evidence limitations, Trump's April 2026 executive order specifically named ibogaine for veterans and allocated $50M in ARPA-H funding. Ex-Navy SEALs and Special Operations veterans were present at the EO signing. This represents a case where a small pilot study with compelling effect sizes in a politically salient population (veterans) drove federal policy and funding commitments ahead of the standard evidence hierarchy that would require Phase 2 and Phase 3 trials. The veteran constituency's political influence created a policy pathway that bypassed the usual requirement for controlled trials before major federal investment. This pattern differs from standard psychedelic development (psilocybin, MDMA) where policy follows rather than precedes Phase 3 evidence.

domains/health/ibogaine-iv-magnesium-protocol-demonstrates-cardiac-risk-manageable-in-supervised-settings-addressing-primary-safety-barrier.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: Stanford's use of intravenous magnesium as QT prolongation prophylaxis resulted in zero serious cardiac events across 30 participants, suggesting the fatal arrhythmia risk can be mitigated
+confidence: experimental
+source: Stanford University ibogaine study (n=30)
+created: 2026-05-10
+title: IV magnesium protocol demonstrates ibogaine's cardiac risk is manageable in supervised clinical settings addressing the primary safety barrier to Phase 3 trials
+agent: vida
+sourced_from: health/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md
+scope: functional
+sourcer: Stanford University School of Medicine
+related: ["healthcare-ai-regulation-needs-blank-sheet-redesign"]
+---
+
+# IV magnesium protocol demonstrates ibogaine's cardiac risk is manageable in supervised clinical settings addressing the primary safety barrier to Phase 3 trials
+
+Ibogaine is known to cause QT prolongation, a potentially fatal heart arrhythmia, with more than 30 deaths reported in the medical literature. This cardiac risk has been the primary barrier to clinical development in regulated settings. The Stanford protocol administered ibogaine with intravenous magnesium specifically to protect cardiac rhythm, and all 30 participants were screened for cardiac risk factors before enrollment. The study reported zero serious cardiac events. While n=30 is too small to definitively establish safety, this represents the first published protocol demonstrating that ibogaine's cardiac risk may be manageable through prophylactic intervention and screening in a hospital-grade clinical environment. The IV magnesium approach is a clinical safety innovation that could enable Phase 3 trial design by addressing the primary regulatory safety concern. This shifts ibogaine from 'too dangerous to study' to 'requires specialized protocol' category, similar to how ketamine's dissociative effects required specialized clinical settings but didn't prevent FDA approval for depression.

domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md

@@ -10,20 +10,18 @@ agent: vida
 scope: structural
 sourcer: American Heart Association
 related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care]]"]
-supports:
-- Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden
-- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation
-- US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden
-- Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement
-reweave_edges:
-- Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden|supports|2026-04-07
-- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation|supports|2026-04-07
-- US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden|supports|2026-04-07
-- Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement|supports|2026-04-10
-sourced_from:
-- inbox/archive/health/2026-01-21-aha-2026-heart-disease-stroke-statistics-update.md
+supports: ["Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden", "Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation", "US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden", "Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement"]
+reweave_edges: ["Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden|supports|2026-04-07", "Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation|supports|2026-04-07", "US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden|supports|2026-04-07", "Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement|supports|2026-04-10"]
+sourced_from: ["inbox/archive/health/2026-01-21-aha-2026-heart-disease-stroke-statistics-update.md"]
+related: ["us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening", "us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements", "us-cardiovascular-mortality-gains-reversing-after-decades-of-improvement-across-major-conditions", "hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022", "hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause"]
 ---
 
 # US CVD mortality is bifurcating with ischemic heart disease declining while heart failure and hypertensive disease reach all-time highs revealing that aggregate improvement masks structural deterioration in cardiometabolic health
 
-The AHA 2026 report reveals a critical bifurcation in CVD mortality trends. While overall age-adjusted CVD mortality declined 33.5% from 1999 to 2023 (350.8 to 218.3 per 100,000), this aggregate improvement conceals opposing trends by disease subtype. Ischemic heart disease and cerebrovascular disease mortality both declined consistently over the study period. However, heart failure mortality reached an all-time high of 21.6 per 100,000 in 2023—exceeding even its 1999 baseline of 20.3 after declining to 16.9 in 2011. Hypertensive disease mortality doubled from 15.8 to 31.9 per 100,000 between 1999-2023, making hypertension the #1 contributing cardiovascular cause of death since 2022, surpassing ischemic heart disease. This pattern indicates that healthcare has become excellent at treating acute ischemic events (MI, stroke) through procedural interventions while simultaneously failing to address the upstream cardiometabolic drivers (obesity, hypertension, metabolic syndrome) that determine long-term healthspan. The bifurcation explains why life expectancy can improve (fewer people dying acutely) while population health deteriorates (more people living with chronic disease burden).
+The AHA 2026 report reveals a critical bifurcation in CVD mortality trends. While overall age-adjusted CVD mortality declined 33.5% from 1999 to 2023 (350.8 to 218.3 per 100,000), this aggregate improvement conceals opposing trends by disease subtype. Ischemic heart disease and cerebrovascular disease mortality both declined consistently over the study period. However, heart failure mortality reached an all-time high of 21.6 per 100,000 in 2023—exceeding even its 1999 baseline of 20.3 after declining to 16.9 in 2011. Hypertensive disease mortality doubled from 15.8 to 31.9 per 100,000 between 1999-2023, making hypertension the #1 contributing cardiovascular cause of death since 2022, surpassing ischemic heart disease. This pattern indicates that healthcare has become excellent at treating acute ischemic events (MI, stroke) through procedural interventions while simultaneously failing to address the upstream cardiometabolic drivers (obesity, hypertension, metabolic syndrome) that determine long-term healthspan. The bifurcation explains why life expectancy can improve (fewer people dying acutely) while population health deteriorates (more people living with chronic disease burden).
+
+## Extending Evidence
+
+**Source:** IHME GBD 2050 Forecast, December 2024
+
+IHME projects ischemic heart disease death rates declining 49.4%, stroke 40.5%, and diabetes 35.7% from 2022-2050, yet overall US life expectancy gains stall at 2.1 years over 28 years. This suggests cardiovascular improvements are being offset by obesity and drug mortality, with the US falling from 49th to 66th globally.

domains/health/us-life-expectancy-projected-stall-2050-obesity-drug-mortality-offset-cvd-gains.md

@@ -0,0 +1,25 @@
+---
+type: claim
+domain: health
+description: "IHME's 2050 forecast shows structural health threats (260M obese Americans, 34% increase in drug deaths) will limit US gains to 2.1 years over 28 years while peer nations improve faster"
+confidence: experimental
+source: IHME Global Burden of Disease 2050 Forecast, December 2024
+created: 2026-05-10
+title: US life expectancy is projected to stall at 80.4 years by 2050 while global ranking drops from 49th to 66th as obesity epidemic and drug mortality resurgence offset cardiovascular improvements
+agent: vida
+sourced_from: health/2024-12-05-ihme-us-life-expectancy-stall-2050-obesity-structural.md
+scope: structural
+sourcer: IHME
+supports: ["Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s", "Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated"]
+related: ["Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s", "Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated", "us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening", "us-healthspan-declining-while-lifespan-recovers-creating-divergence", "cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths", "us-cardiovascular-mortality-gains-reversing-after-decades-of-improvement-across-major-conditions", "us-healthspan-lifespan-gap-largest-globally-despite-highest-spending"]
+---
+
+# US life expectancy is projected to stall at 80.4 years by 2050 while global ranking drops from 49th to 66th as obesity epidemic and drug mortality resurgence offset cardiovascular improvements
+
+IHME's Global Burden of Disease 2050 forecast projects US life expectancy will reach only 80.4 years by 2050, up from 78.3 in 2022—a gain of just 2.1 years over 28 years. More significantly, the US global ranking will drop from 49th to 66th as other nations improve faster. This stall occurs despite projected improvements in cardiovascular mortality: ischemic heart disease deaths declining 49.4%, stroke 40.5%, and diabetes 35.7% from 2022-2050.
+
+The structural threats offsetting these gains are obesity and drug mortality. IHME forecasts 260 million Americans will be affected by obesity by 2050, with obesity accelerating biological aging by more than 2 years in nonsmoking adults. Drug use disorder death rates are projected to increase 34% from 19.9 per 100K (2022) to 26.7 per 100K (2050)—the highest rate globally, more than twice Canada's rate.
+
+This forecast provides critical context for the 2024 CDC life expectancy all-time high of 79.0 years. The IHME model treats the 2024 improvement as partially cyclical (COVID dissipation plus fentanyl supply disruption) rather than structural resolution. The divergence between acute mortality improvement (CDC 2024) and structural disease burden trajectory (IHME 2050) suggests the binding constraints on US healthspan remain obesity-driven metabolic disease and socioeconomic drivers of drug mortality, even as acute cardiovascular care improves.
+
+The global ranking decline is particularly revealing: it indicates the US is not declining absolutely but failing to address structural risk factors as effectively as peer nations. The 2050 projection assumes current policy trajectories continue—it does not account for potential GLP-1 scale effects, major policy reforms, or fentanyl supply dynamics that could alter the trajectory.

entities/health/stanford-ibogaine-veterans-study.md

@@ -0,0 +1,36 @@
+---
+type: entity
+entity_type: research_program
+name: Stanford Ibogaine Veterans Study
+domain: health
+status: completed
+---
+
+# Stanford Ibogaine Veterans Study
+
+## Overview
+Stanford University School of Medicine pilot study investigating ibogaine for veterans with PTSD, traumatic brain injury, and/or substance use disorder.
+
+## Key Details
+- **Design**: n=30 veterans, uncontrolled pilot, overseas clinical setting (ibogaine is Schedule I in US)
+- **Innovation**: IV magnesium protocol for QT prolongation prophylaxis
+- **Primary outcome**: 1-month self-reported symptom reduction
+- **Results**: 88% PTSD reduction, 87% depression reduction, 81% anxiety reduction
+- **Safety**: Zero serious cardiac events with magnesium protocol
+
+## Evidence Limitations
+- No control group (no placebo comparison)
+- Single timepoint (1 month only, no durability data)
+- Non-representative population (veteran-specific)
+- Self-reported outcomes (expectancy bias risk)
+- Small sample size (n=30)
+
+## Policy Impact
+Despite evidence limitations, this study was specifically cited in Trump's April 2026 executive order allocating $50M in ARPA-H funding for ibogaine research in veterans. Ex-Navy SEALs and Special Operations veterans were present at EO signing.
+
+## Timeline
+- **2024** — Study published, first hospital-grade ibogaine protocol with cardiac safety measures
+- **2026-04** — Trump EO names ibogaine for veterans, $50M ARPA-H funding commitment
+
+## Significance
+Represents first peer-reviewed evidence that ibogaine's cardiac risk (QT prolongation) may be manageable in supervised clinical settings through prophylactic intervention. Also demonstrates how politically salient populations (veterans) can drive federal policy ahead of standard evidence hierarchies (Phase 3 trials).

inbox/archive/health/2024-12-05-ihme-us-life-expectancy-stall-2050-obesity-structural.md

@@ -7,10 +7,13 @@ date: 2024-12-05
 domain: health
 secondary_domains: []
 format: research-report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-10
 priority: medium
 tags: [life-expectancy, IHME, GBD, 2050-forecast, obesity, metabolic-disease, drug-use, structural-health, US-global-ranking, chronic-disease]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md

@@ -7,10 +7,13 @@ date: 2024-01-01
 domain: health
 secondary_domains: []
 format: research-summary
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-10
 priority: medium
 tags: [ibogaine, PTSD, veterans, TBI, clinical-research, psychedelic, opioid-addiction, cardiac-safety, Stanford, executive-order]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content